67 related articles for article (PubMed ID: 19151561)
1. [Lung cancer].
Ayabe E; Kaira K; Yamamoto N
Gan To Kagaku Ryoho; 2009 Jan; 36(1):21-5. PubMed ID: 19151561
[TBL] [Abstract][Full Text] [Related]
2. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for lung cancer: clinical uses.
Greenberg AK; Lee MS
Curr Opin Pulm Med; 2007 Jul; 13(4):249-55. PubMed ID: 17534168
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
7. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
8. [Biomarker for chemotherapy in patients with colorectal cancer].
Matsusaka S
Gan To Kagaku Ryoho; 2009 Jan; 36(1):11-4. PubMed ID: 19151559
[TBL] [Abstract][Full Text] [Related]
9. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
Hirsch FR
Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
[TBL] [Abstract][Full Text] [Related]
10. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
[TBL] [Abstract][Full Text] [Related]
11. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer genotype-based therapy and predictive biomarkers: present and future.
Cagle PT; Allen TC
Arch Pathol Lab Med; 2012 Dec; 136(12):1482-91. PubMed ID: 23194040
[TBL] [Abstract][Full Text] [Related]
13. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
14. Effect of verapamil on the expression of EGFR and NM23 in A549 human lung cancer cells.
Zhang C; Lv F; Zhou L; Li X; Wu XX; Hoffman RM
Anticancer Res; 2009 Jan; 29(1):27-32. PubMed ID: 19331130
[TBL] [Abstract][Full Text] [Related]
15. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
Yung TK; Chan KC; Mok TS; Tong J; To KF; Lo YM
Clin Cancer Res; 2009 Mar; 15(6):2076-84. PubMed ID: 19276259
[TBL] [Abstract][Full Text] [Related]
16. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
[TBL] [Abstract][Full Text] [Related]
18. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A; Kobayashi K; Usui K; Maemondo M; Okinaga S; Mikami I; Ando M; Yamazaki K; Saijo Y; Gemma A; Miyazawa H; Tanaka T; Ikebuchi K; Nukiwa T; Morita S; Hagiwara K;
J Clin Oncol; 2009 Mar; 27(9):1394-400. PubMed ID: 19224850
[TBL] [Abstract][Full Text] [Related]
19. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.
Cho WC; Chow AS; Au JS
Eur J Cancer; 2009 Aug; 45(12):2197-206. PubMed ID: 19493678
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
